|
|
||||||||


*
Department of Molecular Genetics and Microbiology, University of Medicine and Dentistry, Robert Wood Johnson Medical School, Piscataway, NJ 08854; and
Division of Therapeutic Proteins, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892
With the use of a partial sequence of the human genome, we
identified a gene encoding a novel soluble receptor belonging to the
class II cytokine receptor family. This gene is positioned on
chromosome 6 in the vicinity of the IFNGR1 gene
in a head-to-tail orientation. The gene consists of six exons and
encodes a 231-aa protein with a 21-aa leader sequence. The secreted
mature protein demonstrates 34% amino acid identity to the
extracellular domain of the IL-22R1 chain. Cross-linking experiments
demonstrate that the protein binds IL-22 and prevents binding of IL-22
to the functional cell surface IL-22R complex, which consists of two
subunits, the IL-22R1 and the IL-10R2c chains. Moreover,
this soluble receptor, designated IL-22-binding protein (BP), is
capable of neutralizing IL-22 activity. In the presence of the IL-22BP,
IL-22 is unable to induce Stat activation in IL-22-responsive human
lung carcinoma A549 cells. IL-22BP also blocked induction of the
suppressors of cytokine signaling-3 (SOCS-3) gene expression by
IL-22 in HepG2 cells. To further evaluate IL-22BP action, we used
hamster cells expressing a modified IL-22R complex consisting of the
intact IL-10R2c and the chimeric IL-22R1/
R1 receptor in
which the IL-22R1 intracellular domain was replaced with the IFN-
R1
intracellular domain. In these cells, IL-22 activates biological
activities specific for IFN-
, such as up-regulation of MHC class I
Ag expression. The addition of IL-22BP neutralizes the ability of IL-22
to induce Stat activation and MHC class I Ag expression in these cells.
Thus, the soluble receptor designated IL-22BP inhibits IL-22 activity
by binding IL-22 and blocking its interaction with the cell surface
IL-22R complex.
This article has been cited by other articles:
![]() |
E. Ziesche, M. Bachmann, H. Kleinert, J. Pfeilschifter, and H. Muhl The Interleukin-22/STAT3 Pathway Potentiates Expression of Inducible Nitric-oxide Synthase in Human Colon Carcinoma Cells J. Biol. Chem., June 1, 2007; 282(22): 16006 - 16015. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Wolk, E. Witte, U. Hoffmann, W.-D. Doecke, S. Endesfelder, K. Asadullah, W. Sterry, H.-D. Volk, B. M. Wittig, and R. Sabat IL-22 Induces Lipopolysaccharide-Binding Protein in Hepatocytes: A Potential Systemic Role of IL-22 in Crohn's Disease J. Immunol., May 1, 2007; 178(9): 5973 - 5981. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. F. Weber, S. Schlautkotter, S. Kaiser-Moore, F. Altmayr, B. Holzmann, and H. Weighardt Inhibition of Interleukin-22 Attenuates Bacterial Load and Organ Failure during Acute Polymicrobial Sepsis Infect. Immun., April 1, 2007; 75(4): 1690 - 1697. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Brand, J. Dambacher, F. Beigel, K. Zitzmann, M. H. J. Heeg, T. S. Weiss, T. Prufer, T. Olszak, C. J. Steib, M. Storr, et al. IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro Am J Physiol Gastrointest Liver Physiol, April 1, 2007; 292(4): G1019 - G1028. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Brand, F. Beigel, T. Olszak, K. Zitzmann, S. T. Eichhorst, J.-M. Otte, H. Diepolder, A. Marquardt, W. Jagla, A. Popp, et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration Am J Physiol Gastrointest Liver Physiol, April 1, 2006; 290(4): G827 - G838. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Boniface, F.-X. Bernard, M. Garcia, A. L. Gurney, J.-C. Lecron, and F. Morel IL-22 Inhibits Epidermal Differentiation and Induces Proinflammatory Gene Expression and Migration of Human Keratinocytes J. Immunol., March 15, 2005; 174(6): 3695 - 3702. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Levine Mechanisms of Soluble Cytokine Receptor Generation J. Immunol., November 1, 2004; 173(9): 5343 - 5348. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P. Donnelly, F. Sheikh, S. V. Kotenko, and H. Dickensheets The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain J. Leukoc. Biol., August 1, 2004; 76(2): 314 - 321. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. A. Whittington, L. Armstrong, K. M. Uppington, and A. B. Millar Interleukin-22: A Potential Immunomodulatory Molecule in the Lung Am. J. Respir. Cell Mol. Biol., August 1, 2004; 31(2): 220 - 226. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Yang, H. Ge, A. Boucher, X. Yu, and C. Li Modulation of Direct Leptin Signaling by Soluble Leptin Receptor Mol. Endocrinol., June 1, 2004; 18(6): 1354 - 1362. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Mantovani, M. Locati, N. Polentarutti, A. Vecchi, and C. Garlanda Extracellular and intracellular decoys in the tuning of inflammatory cytokines and Toll-like receptors: the new entry TIR8/SIGIRR J. Leukoc. Biol., May 1, 2004; 75(5): 738 - 742. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Peleg-Shulman, L. C. Roisman, G. Zupkovitz, and G. Schreiber Optimizing the Binding Affinity of a Carrier Protein: A CASE STUDY ON THE INTERACTION BETWEEN SOLUBLE ifnar2 AND INTERFERON {beta} J. Biol. Chem., April 23, 2004; 279(17): 18046 - 18053. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Sheikh, V. V. Baurin, A. Lewis-Antes, N. K. Shah, S. V. Smirnov, S. Anantha, H. Dickensheets, L. Dumoutier, J.-C. Renauld, A. Zdanov, et al. Cutting Edge: IL-26 Signals through a Novel Receptor Complex Composed of IL-20 Receptor 1 and IL-10 Receptor 2 J. Immunol., February 15, 2004; 172(4): 2006 - 2010. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Dumoutier, C. Leemans, D. Lejeune, S. V. Kotenko, and J.-C. Renauld Cutting Edge: STAT Activation By IL-19, IL-20 and mda-7 Through IL-20 Receptor Complexes of Two Types J. Immunol., October 1, 2001; 167(7): 3545 - 3549. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |